塞力斯医疗科技集团股份有限公司 对外投资管理制度 塞力斯医疗科技集团股份有限公司 对外投资管理制度 （2025 年 8 月） 第一章 总则 司具体情况制定本制度。 第二条 本制度所称对外投资是指公司对外进行的投资行为。即公司将货币 资金以及经资产评估后的房屋、机器、设备、物资等实物，以及专利权、商标权、 土地使用权等无形资产作价出资，进行各种形式的投资活动。 第三条 建立本制度旨在建立有效的管理机制，对公司在组织资源、资产、 投资等经营运作过程中进行效益促进和风险控制，保障资金运营的收益性和安全 性，提高公司的盈利能力和抗风险能力。 第四条 对外投资的原则： （一）必须遵循国家法律、法规的规定； （二）必须符合公司的发展战略； 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"）对外 投资的管理，规范公司对外投资行为，提高资金运作效率，保障公司对外投资的 保值、增值，依据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人 民共和国证券法》《上海证券交易所股票上市规则》等法律、法规及《塞力斯医 疗科技集团股份有限公司章程》 （以下简称"《公司章程》"）的规定，并结合本公 （三）必须规模 ...

塞力斯医疗科技集团股份有限公司 防范控股股东、实际控制人及关联方资金占用管理办法 塞力斯医疗科技集团股份有限公司 第三条 本办法适用于公司（含合并报表范围内子公司）与控股股东、实际 控制人及关联方之间的资金往来。 第四条 控股股东、实际控制人及其他关联方不得以任何方式侵占公司利益。 第五条 本办法所称资金占用包括经营性资金占用和非经营性资金占用。 经营性资金占用指：控股股东、实际控制人及关联方通过采购、销售、相互 提供劳务等生产经营环节的关联交易产生的资金占用。 非经营性资金占用指：为控股股东、实际控制人及关联方垫付工资与福利、 保险、广告等期间费用；为控股股东、实际控制人及关联方以有偿或无偿的方式， 直接或间接地拆借资金；代偿债务及其他在没有商品和劳务对价情况下，提供给 控股股东、实际控制人及关联方使用的资金；与控股股东、实际控制人及关联方 互相代为承担成本和其他支出等。 防范控股股东、实际控制人及关联方资金占用管理办法 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"）与 控股股东、实际控制人及关联方资金往来，建立防范控股股东、实际控制人及关 联方占用 ...

董事及高级管理人员离职管理制度 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"或"本 公司"）董事、高级管理人员离职管理，保障公司治理稳定性及股东合法权益， 根据《中华人民共和国公司法》《上市公司章程指引》等有关法律、法规、规范 性文件和《塞力斯医疗科技集团股份有限公司章程》 （以下简称"公司章程"）的 规定，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员的辞任、 任期届满、解任等离职情形。 第二章 离职情形与生效条件 塞力斯医疗科技集团股份有限公司 董事及高级管理人员离职管理制度 塞力斯医疗科技集团股份有限公司 第三条 董事可以在任期届满以前辞任。董事辞任应向董事会提交书面辞职 报告，公司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 如因董事的辞任导致公司董事会低于法定最低人数时，在改选出的董事就任 前，原董事仍应当依照法律、行政法规、部门规章和本章程规定，履行董事职务。 第四条 董事任期届满未获连任的，自股东会决议通过之日自动离职。 第五条 股东会可以决议解任董事，决议作出之日解任生效。 无正当理由，在任期 ...

塞力斯医疗科技集团股份有限公司 独立董事工作制度 塞力斯医疗科技集团股份有限公司 独立董事工作制度 （2025 年 8 月） 第一条 为进一步完善塞力斯医疗科技集团股份有限公司（以下简称"公司"） 的法人治理结构，强化对董事会、管理层的监督约束机制，促进公司的规范运作， 更好地保护中小股东的合法权益，根据《中华人民共和国公司法》《中华人民共 和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办法》（以 下简称"《独董办法》"）、《上海证券交易所股票上市规则》（以下简称"《股 票上市规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）等 相关规定，制定本制度。 第二条 独立董事是指不在公司担任除独立董事外的任何其他职务，并与公 司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独立客观判断关系的董事。 第三条 公司董事会设立独立董事，独立董事由股东会选举或更换。独立董 事对公司及全体股东负责。独立董事应当独立履行职责，不受公司及公司主要股 东、实际控制人等单位或者个人的影响。 第四条 ...

Core Viewpoint - Tianjin is leveraging its open and inclusive spirit to drive high-quality development, particularly in the context of hosting the upcoming Shanghai Cooperation Organization (SCO) summit, enhancing its global connectivity and collaboration with various countries [2][4]. Group 1: Economic Development and Trade - Tianjin's port serves as a crucial gateway for international trade, maintaining trade relations with over 500 ports in more than 180 countries and regions [4]. - In the first seven months of this year, Tianjin's total import and export volume with SCO countries exceeded 53.3 billion yuan, marking a year-on-year increase of 5.2%, with exports alone reaching over 41.7 billion yuan, up 9.9% [5]. - The establishment of direct shipping lines, such as the "Cherry Express" from South America, has facilitated the import of various fruits into China, showcasing Tianjin's role in global supply chains [5]. Group 2: Foreign Investment and Cooperation - Tianjin has attracted significant foreign investment, exemplified by the establishment of the first wholly foreign-owned tertiary hospital in China, which aims to enhance the quality of healthcare services [6]. - The city has also exported its development model, such as the "Teda Model," to international projects like the China-Egypt TEDA Suez Economic and Trade Cooperation Zone [7]. Group 3: Innovation and Technology - Tianjin is focusing on technological innovation to drive economic growth, with significant increases in revenue from high-tech services and strategic emerging industries, showing growth rates of 16.1%, 17.4%, and 20.1% respectively [8]. - The city is also implementing digital technologies, such as digital twin technology in collaboration with Kazakhstan, to enhance industrial efficiency [9]. Group 4: Sustainable Development - Tianjin is committed to green development, with 243 national-level green manufacturing units and initiatives to optimize energy structures and reduce carbon emissions [10]. - The city has achieved a comprehensive utilization rate of industrial solid waste of over 98% and has built 286,900 charging stations for electric vehicles, leading the national average [10]. Group 5: Urban Governance and Infrastructure - Tianjin is undertaking significant urban renewal projects in preparation for the SCO summit, enhancing the city's infrastructure and aesthetics through meticulous urban management [11][12]. - The city is leveraging smart city technologies to improve urban governance, integrating data from various departments to enhance service delivery [13]. Group 6: Community Engagement and Cultural Exchange - The city is actively involving its citizens in the preparations for the SCO summit, promoting community participation in urban renewal and cultural exchange initiatives [15]. - Tianjin has established friendly city relationships with 20 cities from SCO member states, fostering educational and cultural exchanges, with over 1,400 students from SCO countries studying in Tianjin [7].

Core Viewpoint - Macro Medical Management (09906.HK) reported a significant decline in comprehensive income for the six months ending June 30, 2025, amounting to RMB 346.8 million, a decrease of RMB 68.4 million or 16.5% year-on-year [1] Financial Performance - The company's profit decreased from RMB 20.3 million in the same period last year to a loss of RMB 0.7 million in the current period [1] - The net profit margin for the six months ending June 30, 2024, and June 30, 2025, were 4.9% and -0.2%, respectively [1]

Group 1: Report Overview - Reported company: Nuotai Biotech [17] - Industry: Medical Services [2] - Research date: August 29, 2025 [17] - Company representatives: Chairman and President Tong Ziquan, Independent Director Liu Jian, Financial Controller Ding Wei, and Board Secretary Zhou Hua [17] Group 2: Research Institutions - Institutions participating in the research: Online investors [2] - Details of research institutions: The reception objects include online investors, and the types involve institution - related personnel and others [20] Group 3: Core Views - AI pharmaceutical cooperation: The company reached a comprehensive strategic cooperation with Shenshi Technology in the first half of the year, aiming to build a "Smart R & D - Precise Manufacturing - Ecological Empowerment" trinity value system, focusing on AI - empowered transformation of the biomedical industry [24] - Business cooperation plans: The BD team is actively expanding overseas big pharma business cooperation, and will disclose relevant progress according to regulations [25] - Contract liability changes: The decrease in contract liability compared to the beginning of the year is mainly due to the company's successive shipments during the period [26] - Revenue structure: The polypeptide API business accounts for a higher proportion of the company's current revenue [26] - Business partnerships: The company has cooperated with multiple leading generic drug companies on projects related to semaglutide and tirzepatide APIs and formulations, with overseas orders contributing more to revenue [26] - Product features: The company has established a solid - liquid fusion - based polypeptide large - scale production technology platform, with advantages in product yield, synthesis efficiency, quality, and cost [29] - Capacity expansion: The company will rely on its international BD team to expand into emerging markets to fill the newly - built capacity [29] Group 4: Other Key Points - Product inventory: The company's inventory includes raw materials, work - in - progress, and finished goods, and details can be found in the 2025 semi - annual report [28] - Market value management: The company's management will focus on the main business with superior resources to return good performance to investors and will apply for delisting the ST label after meeting the relevant conditions [27][29] - Regulatory response: The company will disclose the progress of the response to the CSRC's administrative penalty notice according to regulations [29]

百花医药分析师会议 调研日期：2025年08月29日 调研行业：医疗服务 参与调研的机构：投资者等 / 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 | | | 例体位次数 4 | 24/40 33 | | FININ EXIAN, BENN, LEWI | | | 極力集团 | | | · 例计以上的 8 | 品机构管 23 | 构市场到断信记 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证 ...

Core Viewpoint - The company, Giant Star Medical Holdings, reported a significant decline in overall revenue and gross profit due to the impact of China's centralized procurement policy on its main revenue source, the medical segment [1] Financial Performance - Total revenue for the six months ending June 30, 2025, decreased by approximately 37.0% year-on-year to RMB 802.6 million [1] - Gross profit fell by about 38.6% year-on-year to RMB 133.7 million [1] - The profit for the period was RMB 11.15 million, a sharp decline from RMB 1.09 billion in the same period last year [1]

集团致力于持续提升营运效率，尤其专注于满足日益增长的高性价比医疗服务需求。集团充分彰显出经 营韧性及适应能力。 格隆汇8月29日丨康健国际医疗(03886.HK)公布中期业绩，2025年上半年，集团录得收入约9.01亿港 元，公司拥有人应占溢利约1272.7万港元，上年同期亏损约4767.6,万港元。 ...